Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial - Authors' reply

Lancet. 2024 Jul 27;404(10450):339-340. doi: 10.1016/S0140-6736(24)01049-3.

Authors

Hope S Rugo¹, Aditya Bardia², Sara Tolaney³

Affiliations

¹ Department of Medicine, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94158, USA. Electronic address: hope.rugo@ucsf.edu.
² David Geffen School of Medicine and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
³ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

PMID: 39067902
DOI: 10.1016/S0140-6736(24)01049-3

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Antineoplastic Agents, Immunological / therapeutic use
Breast Neoplasms* / drug therapy
Breast Neoplasms* / pathology
Camptothecin / administration & dosage
Camptothecin / analogs & derivatives
Camptothecin / therapeutic use
Female
Humans
Immunoconjugates
Neoplasm Metastasis

Substances

Antibodies, Monoclonal, Humanized
sacituzumab govitecan
Camptothecin
Antineoplastic Agents, Immunological
Immunoconjugates